Longevity Research: Billion-Dollar Competition to Reverse Aging

The Longevity Field's $13 Billion Reality Check
Three decades of aging research just converged on a single trial in Texas — and the drugs being tested were never designed to fight aging.

The most important longevity experiment in history won't involve gene therapy or cellular reprogramming. VITAL-H, a $38 million ARPA-H trial at UT Health San Antonio, will test three pharmacy-shelf drugs — rapamycin, semaglutide, and dapagliflozin — against placebo in 726 healthy adults aged 60-65. It's the first head-to-head comparison of longevity candidates in humans, and every compound was invented for something else entirely.

This pivot toward repurposed drugs isn't a retreat — it's what the evidence demanded. The field spent $13.1 billion in three years on purpose-built aging interventions, and the results were sobering. Calico burned $2.5B of Google's money across five failed trials before AbbVie walked away. Unity Biotechnology, the first senolytic to reach the clinic, dissolved. Harvard's Gladyshev lab found chemical reprogramming causes toxic lipid accumulation in mice at effective doses. The direct assault on aging kept breaking against the wall of translation.

Meanwhile, drugs built for diabetes were quietly producing the strongest anti-aging signal in the field. A Phase 2b RCT showed semaglutide slowing biological aging across four independent epigenetic clocks — the first randomized evidence, not observational data. Tirzepatide showed 85-88% lower dementia risk versus semaglutide in 290,000 patients. And the GLP-1 plus SGLT2 inhibitor combination reversed carotid artery aging more effectively than either drug alone: artery walls shrank 10.7%, amyloid-beta dropped 50%.

The senolytics field — once the great hope of geroscience — hit its own reality check. Two human trials found dasatinib plus quercetin did not reverse any epigenetic clock; several actually accelerated. This doesn't mean clearing senescent cells is useless, but the field's favorite biomarker can't tell if it's working. New tools are arriving: NIH's SenNet atlas covers 15 organs, and blood-based tests can now predict which organs age fastest in a given person.

Basic science kept delivering surprises. A mitochondrial protein that optimizes energy-factory assembly extended mouse lifespan 6.6% — a mechanism nobody had targeted. A Howard Hughes team reprogrammed gut bacteria with antibiotic microdoses to produce longevity compounds without entering the bloodstream. And gene therapy aimed at memory neurons reversed cognitive aging in mice, sidestepping the toxicity of whole-tissue reprogramming. The pattern is now unmistakable: the biggest advances keep coming from unexpected directions, not billion-dollar moonshots.